重度主动脉瓣狭窄合并慢性冠状动脉疾病患者经导管主动脉瓣置换术同期/分期经皮冠状动脉介入治疗救治策略的研究进展  

Research progress on treatment strategies for simultaneous/staged percutaneous coronary intervention in patients with severe aortic valve stenosis and chronic coronary artery disease undergoing percutaneous aortic valve replacement surgery

作　　者：马玲 王婧雅 徐倩伟 余小林[2,3] MA Ling;WANG Jing-ya;XU Qian-wei;YU Xiao-lin(Graduate School of Xinjiang Medical University,Urumqi 830001,China;Department of Cardiology,People’s Hospital of Xinjiang Uyghur Autonomous Region,Urumqi 830001,China;Xinjiang Key Laboratory of Cardiovascular Homeostasis and Regeneration Research,Urumqi 830001,China)

机构地区：[1]新疆医科大学研究生学院,新疆乌鲁木齐830001 [2]新疆维吾尔自治区人民医院心脏及泛血管诊疗中心,新疆乌鲁木齐830001 [3]新疆心脏血管稳态与再生医学研究重点实验室,新疆乌鲁木齐830001

出　　处：《中国介入心脏病学杂志》2024年第5期271-275,共5页Chinese Journal of Interventional Cardiology

摘　　要：目前,经导管主动脉瓣置换术(TAVR)已不仅仅是外科高危重度主动脉瓣狭窄(AS)患者的优选替代方案,中危和低危AS患者也有所获益。近1/2的AS患者合并冠状动脉疾病(CAD),因此在TAVR治疗重度AS合并CAD的患者中行经皮冠状动脉介入治疗(PCI)成为临床常见需求。当前TAVR与PCI孰先孰后亦或同期进行存在较大争议。本文将对行TAVR治疗的重度AS合并慢性CAD患者行PCI的时机进行综述。Currently,transcatheter aortic valve replacement(TAVR)is not only the preferred alternative for highrisk and severe aortic stenosis(AS)patients in surgery,but also benefits patients with moderate and lowrisk AS.Nearly half of AS patients have coronary artery disease(CAD),so percutaneous coronary intervention(PCI)has become a common clinical requirement in patients with severe AS combined with CAD treated with TAVR.There is significant controversy over which TAVR or PCI should be prioritized or conducted simultaneously.This article will review the timing of PCI treatment for severe AS patients with chronic CAD who undergo TAVR treatment.

关 键 词：主动脉瓣狭窄 经导管主动脉瓣置换术 经皮冠状动脉介入治疗 

分 类 号：R541[医药卫生—心血管疾病]